Tildrakizumab was approved in March 2018 for: (A) Psoriasis, (B) HIV, (C) Rheumatoid ahritis, (D) Hepatitis C
Answer is A. Tildrakizumab was designed to block interleukin-23, a cytokine that plays an impoant role in managing the immune system and autoimmune disease. It is approved for the treatment of moderate-to-severe plaque psoriasis.Ref: